Authum Investment & Infrastructure Limited (AIIL) has announced a strategic move into the pharmaceutical sector by signing an investment agreement to acquire a 3% stake in Serovia Pharma Private Limited. The deal, valued at INR 300.00 crores, involves the subscription of compulsorily convertible preference shares (CCPS) in the newly formed pharmaceutical company.

Deal Structure

• AIIL will subscribe to 18,95,053 Series B CCPS of Serovia Pharma
• Each CCPS has a face value of INR 10.00 with a premium of INR 1,573.07
• Total price per share: INR 1,583.07
• Payment will be made in two equal installments of 50% each

About Serovia Pharma

• Incorporated on July 19, 2025
• Focuses on developing, manufacturing, and distributing pharmaceutical products globally
• Plans to expand presence to Cyprus and the United States
• Registered office: Cepha Block 1st Floor, Sy No, 152/6&154/6 Dorasni Palya, Bannerghatta Road, Bangalore - 560076, Karnataka, India

Transaction Details

• Agreement signed on September 15, 2025
• Expected completion date: September 20, 2025
• Subject to pre-closing conditions, including board and shareholder approvals

Strategic Implications

Amit Dangi, Whole Time Director of Authum Investment & Infrastructure Limited, stated that this acquisition aligns with the company's portfolio diversification strategy. The investment targets sectors with stability and growth potential, aiming to create value for stakeholders and ensure a sustainable, profitable future for the company.

Regulatory Compliance

The transaction has been disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. AIIL has informed both the BSE and the National Stock Exchange of India Limited about this strategic investment.

Authum Investment & Infrastructure Limited (AIIL) has made a strategic move in the healthcare sector by entering into a Share Subscription cum Purchase Agreement (SSPA) with Rivaara Labs Private Limited. The deal, valued at Rs 36.57 crore, will see Authum acquiring a 35.09% stake in Rivaara Labs, a company specializing in diagnostic services.

Transaction Details

The transaction involves two key components:

1. Primary Infusion: Authum will subscribe to 3.6 crore cumulative compulsorily convertible participating preference shares (CCPS) of Rivaara Labs for Rs 36.00 crore.
2. Share Purchase: Authum will acquire existing shares from current shareholders for Rs 0.57 crore. This includes:
   • 1.58 crore equity shares
   • 4.10 crore CCPS

Upon completion, Authum will hold a total of 7.70 crore CCPS and 1.58 crore equity shares, granting it 35.09% of the total voting rights in Rivaara Labs.

About Rivaara Labs

Rivaara Labs Private Limited, incorporated on October 18, 2019, operates in the diagnostic services sector. Its business activities include:

• Establishing and operating diagnostic service centers for pathology, imaging, PCR testing, and genomic sequencing
• Distribution, marketing, and manufacturing of point-of-care diagnostic kits and equipment based on molecular biology in India
• Providing RT-PCR related diagnostic services
• Offering digital healthcare products and services related to diagnostics

Financial Overview

As of March 31, 2025, Rivaara Labs reported:

• Net Worth: Rs (3,482.93) lakh (negative)
• Turnover: Rs 2,552.69 lakh

The company's turnover for the past three fiscal years:

Strategic Implications

This acquisition aligns with Authum Investment & Infrastructure's long-term strategy of diversifying its portfolio while investing in sectors with stability and growth potential. The company aims to nurture and expand this business, focusing on value creation for all stakeholders and ensuring a sustainable, profitable future.

Transaction Timeline

The acquisition is expected to be completed by September 30, 2025, subject to the fulfillment of conditions precedent, including board and shareholder approvals of Rivaara Labs.

Regulatory Compliance

The transaction does not fall under related party transactions, and no governmental or regulatory approvals are anticipated to be required for the acquisition.

Authum Investment & Infrastructure Limited has disclosed this information in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating transparency in its corporate actions.

As the healthcare and diagnostics sector continues to evolve, this strategic investment by Authum in Rivaara Labs could potentially strengthen its position in the growing Indian healthcare market.